ME Therapeutics(AXSM)
NEW YORK, NYBiotechnology
Focus: ME Therapeutics is a publicly traded biotech (AXSM) founded in 2023, focused on immunooncology drugs targeting novel myeloid cell targets. The company operates with $315M in cash and is in early-stage development with a diverse but unfocused pipeline.
Profile data last refreshed 8m ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Total Funding
$1B
Open Jobs
0
About ME Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow ME Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from ME Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$271M
Pipeline & Clinical Trials
The Myelin Disorders Biorepository Project
LeukodystrophyMindfulness and Meditation-Based Relapse Prevention Program
Substance Use DisordersClinical Trials (1)
Help build intelligence for ME Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.